Wednesday, May 25, 2022

< + > Paxlovid Paradox, Part 1: Trying to Outrun COVID-19

The dilemma is heart-rending. With COVID-19 infections and hospitalizations rising, the FDA approved two drugs—Paxlovid from Pfizer, and molnupiravir from Merck and Ridgeback—to treat the illness that is killing so many and rendering others permanently disabled. Yet in the United States, many patients can’t get the drug, or even figure out which pharmacy near them […]

No comments:

Post a Comment

< + > What's behind EHR-induced clinician burnout? And how to solve it?

When evaluating electronic health record systems to minimize documentation burden, usability is always the big challenge, says one informati...